Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Impax Laboratories, Inc.
Current Parent Company: Amneal Pharmaceuticals
Penalty: $37,500,000
Year: 2018
Date: July 18, 2018
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Impax agreed to pay $37.5 million to direct purchaser plaintiffs to settle allegations relating to its role in an arrangement to delay launching a generic version of the acne medication Solodyn.
Level of Government: federal
Action Type: private litigation
Court: District of Massachusetts
Civil or Criminal Case: civil
Case ID: 1:14-md-02503
Case Name: In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: New Jersey
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.